Imago BioSciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Hugh Young Rienhoff Jr.,
- Full Time Employees
- 41
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 329 Oyster Point Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Jul 16, 2021
- CIK
- 0001623715
- Website
- imagobio.com
- Similar Companies
- Business
- Imago BioSciences, Inc. (IMGO) develops precision medicines targeting mast cell-mediated diseases and fibrotic disorders. The company offers pipeline candidates including bomedemstat, a late-stage oral small molecule inhibitor of lysine-specific demethylase-1 (LSD1) for nonadvanced systemic mastocytosis, polycythemia vera, and essential thrombocythemia; IMG-007, an intravitreal anti-KIT antibody for advanced dry age-related macular degeneration; and IMG-004, a topical LSD1 inhibitor for atopic dermatitis. These products focus on novel mechanisms to address unmet needs in rare diseases and ophthalmology through targeted inhibition of disease-driving pathways. Founded in 2018 and headquartered in South San Francisco, California, Imago operates primarily in the United States with clinical trials conducted globally in North America and Europe. In recent developments, the company advanced bomedemstat into Phase 3 trials for polycythemia vera in 2024 following positive Phase 2 data, expanded its LSD1 franchise with new topical formulations, and formed a strategic research collaboration with a leading academic institution to explore mast cell modulators in 2025.
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
These Were the 5 Best and Worst Performing Small-Cap Stocks in November 2022
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
Imago BioSciences: The Bone Marrow Cancer Researcher Reaches Milestone
IMAGO BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Imago BioSciences, Inc. - IMGO
Imago (IMGO) Shares Surge 104% on Buyout Offer From Merck
SHAREHOLDER ALERT: Weiss Law Investigates Imago BioSciences, Inc.
Imago BioSciences Catapults To Record High On Merck's $1.35 Billion Buyout
Merck Making Moves, to Acquire Imago Biosciences
Why Merck (MRK) Is Buying Imago BioSciences (IMGO) For $1.35 Billion
Imago BioSciences Stock Surges. It's Being Bought by Merck.
Imago BioSciences stock soars after Merck bids more than 100% premium to buy the biotech
Merck to Acquire Imago BioSciences, Inc.
Imago BioSciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Imago BioSciences to Participate in Upcoming Investor Conferences
Why Earnings Season Could Be Great for Imago BioSciences (IMGO)
Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference
Imago BioSciences Receives Orphan Designation From European Medicines Agency for Bomedemstat for the Treatment of Essential Thrombocythemia
Imago BioSciences, Inc. Announces Closing of $134.4 Million Initial Public Offering
7 Companies Begin Trading. Here's How They're Doing.